David Reese
Chief Executive Officer chez CHEMOCENTRYX, INC.
Fortune : 17 M $ au 31/03/2024
Profil
Fondateur de Translational Oncology Research International, Inc, David M. Reese est vice-président exécutif chargé de la recherche et du développement chez Amgen, Inc. Le Dr Reese a précédemment occupé le poste de directeur de la recherche clinique chez Breast Cancer International Research Group Ltd. et de directeur de la recherche clinique chez Translational Research In Oncology. Il a obtenu un diplôme de premier cycle du Harvard College et un diplôme de premier cycle de la faculté de médecine de l'Université de Cincinnati.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
AMGEN INC.
0,01% | 18/03/2024 | 60 666 ( 0,01% ) | 17 M $ | 31/03/2024 |
Postes actifs de David Reese
Sociétés | Poste | Début |
---|---|---|
AMGEN INC. | Chief Tech/Sci/R&D Officer | 26/07/2018 |
FIVE PRIME THERAPEUTICS, INC. | Chief Executive Officer | - |
CHEMOCENTRYX, INC. | Chief Executive Officer | - |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Chief Executive Officer | - |
BioVex Group, Inc.
BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | President | - |
CEO Roundtable on Cancer, Inc.
CEO Roundtable on Cancer, Inc. Miscellaneous Commercial ServicesCommercial Services CEO Roundtable on Cancer, Inc. promotes activities to reduce cancer risk, enable early detection, facilitate better access to treatment and hasten the discovery. Its programs include CEO cancer gold standard, life sciences consortium and project data sphere. The company was founded by George H. W. Bush in 2001 and is headquartered in Durham, NC. | Director/Board Member | - |
KAI Pharmaceuticals, Inc.
KAI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology KAI Pharmaceuticals, Inc. discovers and develops biopharmaceutical drugs. It is a multiple, novel clinical-stage programs in the areas of cardiovascular, renal, and pain. The company was founded in 2002 and is headquartered in South San Francisco, CA. | Chief Executive Officer | - |
Alantos Pharmaceuticals Holding, Inc.
Alantos Pharmaceuticals Holding, Inc. Pharmaceuticals: MajorHealth Technology Alantos Pharmaceuticals Holding, Inc. manufactures bio-pharmaceutical products. The firm develops small molecule compounds for inflammatory cytokine pathways. The company was founded in 1999 and is headquartered in Thousand Oaks, CA. | President | - |
Research!America
Research!America Miscellaneous Commercial ServicesCommercial Services Research!America is a lobbying firm. The non-profit company is based in Alexandria, VA. The CEO of the company is Mary Woolley. | Director/Board Member | 22/04/2023 |
Anciens postes connus de David Reese
Sociétés | Poste | Fin |
---|---|---|
░░░░░░░░░░░░░ ░░░░░░░░ ░░░░░░░░ ░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░ ░░░░░░░░░░░░░ ░░░░░░░░ ░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░░░ ░░░░░░░░ ░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formation de David Reese
The University of Cincinnati College of Medicine | Undergraduate Degree |
Harvard College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
AMGEN INC. | Health Technology |
Entreprise privées | 11 |
---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
ChemoCentryx, Inc.
ChemoCentryx, Inc. Pharmaceuticals: MajorHealth Technology ChemoCentryx, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in San Carlos, CA. | Health Technology |
KAI Pharmaceuticals, Inc.
KAI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology KAI Pharmaceuticals, Inc. discovers and develops biopharmaceutical drugs. It is a multiple, novel clinical-stage programs in the areas of cardiovascular, renal, and pain. The company was founded in 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
Alantos Pharmaceuticals Holding, Inc.
Alantos Pharmaceuticals Holding, Inc. Pharmaceuticals: MajorHealth Technology Alantos Pharmaceuticals Holding, Inc. manufactures bio-pharmaceutical products. The firm develops small molecule compounds for inflammatory cytokine pathways. The company was founded in 1999 and is headquartered in Thousand Oaks, CA. | Health Technology |
BioVex Group, Inc.
BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Health Technology |
CEO Roundtable on Cancer, Inc.
CEO Roundtable on Cancer, Inc. Miscellaneous Commercial ServicesCommercial Services CEO Roundtable on Cancer, Inc. promotes activities to reduce cancer risk, enable early detection, facilitate better access to treatment and hasten the discovery. Its programs include CEO cancer gold standard, life sciences consortium and project data sphere. The company was founded by George H. W. Bush in 2001 and is headquartered in Durham, NC. | Commercial Services |
Research!America
Research!America Miscellaneous Commercial ServicesCommercial Services Research!America is a lobbying firm. The non-profit company is based in Alexandria, VA. The CEO of the company is Mary Woolley. | Commercial Services |
Translational Oncology Research International, Inc. | Health Technology |
Breast Cancer International Research Group Ltd. | |
Translational Research In Oncology |